BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024

BioAtla, Inc.

Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.
Cash $111.5M at year-end 2023; expected to fund operations into 2H 2025.
CAB-CTLA-4 (BA3071) cleared DLT at 700 mg; Phase 2 monotherapy data due 2Q 2024.
CAB-ROR2-ADC (BA3021) Phase 2 melanoma/SCCHN fully enrolled; data readouts in May.
CAB-AXL-ADC (BA3011) UPS registration trial enrollment ~20 patients due April; FDA meeting 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.